Maria S. Felice

TL;DR: Patients treated with the hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL, and Delayed intensification of chemotherapy did not benefit patients.

TL;DR: Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy, and the gap between the two strategies increases as the risk profile of the patient worsens.

TL;DR: Even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19, and the intensity of preventive measures should not cause delays or obstructions in oncological treatment.

TL;DR: HSCT seems to be a valuable option for a subgroup of infant MLL(+) acute lymphoblastic leukemia carrying further poor prognostic factors and is associated with a 64% reduction in the risk of failure resulting from relapse or death in CR.

TL;DR: The association of lineage switches with MLL gene alterations and the involvement of a common lymphoid B‐myeloid precursor is supported, and new therapies should be designed to address these rare cases.